{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 56,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 10,
  "notes": "The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/19",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.4,
        "y": 0.7
      },
      "kind": "callout",
      "text": "Total of 13/39 responses 33.3% ORR",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42c968ba-cdf1-45fb-88ab-c6662c52d338",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*De Braud et al AACR 2022 # Lebbe et al ESMO 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a92f1dc4-61e4-41da-b469-6d2e0002f2b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.82,
        "x": 0.09,
        "y": 0.305
      },
      "kind": "table",
      "text": "Study, Data Cutoff, ORR, DCR, DOR, Source. Phase 1 (LXH254X2102*), 9 Dec 2021, 7/15 (46.7%), 12/15 (80.0%), 3.75 mo, AACR 2022. Phase 2 (LXH254C12201#), 4 July 2022, 6/24 (25.0%), 17/24 (70.8%), NA, ESMO 2022",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee2acda6-0417-4a13-9eea-5f33c3e2c085",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Clinical activity of naporafenib + trametinib in NRASm melanoma was reproducible across Phase 1 and Phase 2 studies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecefe43c-8108-4cc8-b29c-9fa1c1bcebf5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6453dffc-b2cc-4c2f-864c-9086c6564015",
      "evidence": "The slide presents a table with study data, including ORR, DCR, and DOR, which is a clear example of a data table.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 16,
      "beatId": "de59f7d9-38c9-46a9-8877-a3655888462f",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Erasca's pipeline and clinical data",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Slides 16-42 present Erasca's pipeline and clinical data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "843a34f0-1c93-40b5-8e7f-36476533a31f",
      "evidence": "Slides 15-20 discuss current treatment limitations and potential for Erasca's pipeline",
      "position": 1,
      "objective": "Highlight the cost of not addressing unmet needs in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}